Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509041 · ClinicalTrials.gov registry record · Phase 2
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00509041 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 46 participants.
The verdict
NCT00509041, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated malignant mesothelioma.
Interventions
- DRUG dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509041
The ClinicalTrials.gov registry entry for NCT00509041 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dasatinib is the first listed.
NCT00509041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509041 about?
NCT00509041 is a clinical study titled "Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma". RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated malignant mesothelioma.
What is the current status of trial NCT00509041?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2007-08. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00509041?
The interventions under investigation include: dasatinib (DRUG).
Who is sponsoring clinical trial NCT00509041?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.